Xenon Pharmaceuticals Inc. (XENE) stock
XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
$38.78−0.48 (-1.22%)
Close on Nov 17, 2026Market cap $3.76BP/E –Yield –
Xenon Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Xenon Pharmaceuticals's cash was $930.69M at Jun 30, 2026. For fiscal 2025 it was $548.89M, down 12.4% from the year before. Over ten years it grew 25.1% a year on average. The highest annual figure on record is $638.08M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $548.89M | -12.4% |
| FY2024 | Dec 31, 2024 | $626.91M | -1.8% |
| FY2023 | Dec 31, 2023 | $638.08M | +7.8% |
| FY2022 | Dec 31, 2022 | $592.09M | +7.3% |
| FY2021 | Dec 31, 2021 | $551.77M | +211.7% |
| FY2020 | Dec 31, 2020 | $177.00M | +25.2% |
| FY2019 | Dec 31, 2019 | $141.36M | +18.5% |
| FY2018 | Dec 31, 2018 | $119.31M | +173.2% |
| FY2017 | Dec 31, 2017 | $43.67M | -31.9% |
| FY2016 | Dec 31, 2016 | $64.15M | +9.4% |
| FY2015 | Dec 31, 2015 | $58.65M | -30.2% |
| FY2014 | Dec 31, 2014 | $84.04M | +70.6% |
| FY2013 | Dec 31, 2013 | $49.28M | -18.1% |
| FY2012 | Dec 31, 2012 | $60.16M | +332.0% |
| FY2011 | Dec 31, 2011 | $13.93M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $930.69M | +90.9% |
| Q1 FY2026 | Mar 31, 2026 | $1.09B | +99.2% |
| Q4 FY2025 | Dec 31, 2025 | $548.89M | -12.4% |
| Q3 FY2025 | Sep 30, 2025 | $462.27M | -29.3% |
| Q2 FY2025 | Jun 30, 2025 | $487.55M | -32.4% |
| Q1 FY2025 | Mar 31, 2025 | $549.63M | -21.4% |
| Q4 FY2024 | Dec 31, 2024 | $626.91M | -1.8% |
| Q3 FY2024 | Sep 30, 2024 | $654.02M | +24.2% |
| Q2 FY2024 | Jun 30, 2024 | $721.54M | +33.7% |
| Q1 FY2024 | Mar 31, 2024 | $699.60M | +32.7% |
| Q4 FY2023 | Dec 31, 2023 | $638.08M | +7.8% |
| Q3 FY2023 | Sep 30, 2023 | $526.67M | -17.5% |
| Q2 FY2023 | Jun 30, 2023 | $539.60M | -31.5% |
| Q1 FY2023 | Mar 31, 2023 | $527.04M | -2.0% |
| Q4 FY2022 | Dec 31, 2022 | $592.09M | +7.3% |
| Q3 FY2022 | Sep 30, 2022 | $638.19M | +155.7% |
| Q2 FY2022 | Jun 30, 2022 | $788.24M | +202.6% |
| Q1 FY2022 | Mar 31, 2022 | $537.94M | +95.8% |
| Q4 FY2021 | Dec 31, 2021 | $551.77M | +211.7% |
| Q3 FY2021 | Sep 30, 2021 | $249.63M | +30.7% |
| Q2 FY2021 | Jun 30, 2021 | $260.52M | +28.5% |
| Q1 FY2021 | Mar 31, 2021 | $274.70M | +19.6% |
| Q4 FY2020 | Dec 31, 2020 | $177.00M | +25.2% |
| Q3 FY2020 | Sep 30, 2020 | $190.93M | +101.8% |
| Q2 FY2020 | Jun 30, 2020 | $202.75M | +99.2% |
| Q1 FY2020 | Mar 31, 2020 | $229.67M | +108.0% |
| Q4 FY2019 | Dec 31, 2019 | $141.36M | +18.5% |
| Q3 FY2019 | Sep 30, 2019 | $94.60M | -25.6% |
| Q2 FY2019 | Jun 30, 2019 | $101.80M | +60.9% |
| Q1 FY2019 | Mar 31, 2019 | $110.43M | +214.8% |
| Q4 FY2018 | Dec 31, 2018 | $119.31M | +173.2% |
| Q3 FY2018 | Sep 30, 2018 | $127.13M | +190.4% |
| Q2 FY2018 | Jun 30, 2018 | $63.27M | +22.4% |
| Q1 FY2018 | Mar 31, 2018 | $35.08M | -39.5% |
| Q4 FY2017 | Dec 31, 2017 | $43.67M | -31.9% |
| Q3 FY2017 | Sep 30, 2017 | $43.77M | -37.0% |
| Q2 FY2017 | Jun 30, 2017 | $51.70M | – |
| Q1 FY2017 | Mar 31, 2017 | $58.03M | – |
| Q4 FY2016 | Dec 31, 2016 | $64.15M | – |
| Q3 FY2016 | Sep 30, 2016 | $69.49M | – |
See a number that looks wrong?